Guardant Health, Inc. (GH) SEC Filings & Earnings Calls

Accumulated deficit and ongoing losses

“we had an accumulated deficit of $3.2 billion.” · word for word

Sales and marketing expense growth outpacing revenue growth

“Sales and marketing expenses were $190.0 million for the three months ended June 30, 2026, compared to $119.6 million for the three months ended June 30, 2025, an increase of $70.4 million, or 59%.” · word for word

Net loss widening despite revenue growth; operating expenses increasing faster than revenue.

“Net loss was $120.1 million for the second quarter of 2026, as compared to $99.9 million” · word for word

Negative free cash flow and increasing cash burn.

“Free cash flow for the second quarter of 2026 was $(69.5) million, as compared to $(65.9) million” · word for word

Commercial infrastructure expansion driving cost growth.

“increase in operating expenses was primarily related to commercial infrastructure expansion and marketing activities” · word for word

Net loss increased year-over-year due to higher operating expenses for commercial expansion.

“Net loss was $112.1 million for the first quarter of 2026, as compared to $95.2 million” · word for word

Operating loss and accumulated deficit

“We have incurred losses and negative cash flows from operations since our inception, and as of March 31, 2026, we had an accumulated deficit of $3.1 billion.” · word for word

Sales and marketing expense growth outpacing revenue growth

“Sales and marketing expenses were $169.1 million for the three months ended March 31, 2026, compared to $104.3 million for the three months ended March 31, 2025, an increase of $64.8 million, or 62%.” · word for word

Reimbursement dependency

“In the United States, we submit claims to Medicare and private payers for reimbursement for our Guardant360 CDx, Guardant360 Liquid, Guardant360 Tissue, and Guardant Reveal tests performed for qualifying patients.” · word for word

Continued operating losses and negative cash flow

“Net loss was $416.3 million for 2025... Free cash flow for 2025 was negative $233.1 million” · word for word

Dependence on Medicare and regulatory reimbursement for Shield

“We achieved advanced diagnostic laboratory test (ADLT) status for Shield, securing a $1,495 Medicare reimbursement rate” · word for word

Concentration of insider ownership and potential governance risk

“All directors and executive officers as a group (18 persons) 7,531,614 5.6%” · word for word

CMO departure could impact clinical strategy and regulatory interactions; no successor named

“resignation of Craig Eagle, M.D., the Company's Chief Medical Officer” · word for word

Continued net losses and negative free cash flow, though improving.

“Net loss was $128.5 million for Q4 2025; free cash flow was $(54.2) million.” · word for word

Operating expenses increasing due to commercial expansion and marketing for Shield launch.

“Operating expenses were $302.6 million for Q4 2025, compared to $250.2 million for Q4 2024.” · word for word

History of losses and uncertain profitability

“We have incurred significant losses since inception, we may continue to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.” · word for word

Dependence on limited number of suppliers

“We rely on a limited number of suppliers or sole suppliers for some of our laboratory instruments and materials and may not be able to find replacements or promptly transition to alternative suppliers.” · word for word

Reimbursement uncertainty

“If third-party payers, including commercial payers and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our tests, our business and results of operations will be negatively affected.” · word for word

Preliminary results subject to change; final audited results may differ materially.

“These amounts are preliminary, unaudited and are thus inherently uncertain and subject to change”

Negative free cash flow indicates ongoing cash burn.

“Preliminary unaudited free cash flow was approximately negative $54 million for the fourth quarter of 2025” · word for word

Share dilution from common stock offering and potential dilution from convertible notes if converted.

“Issued unregistered shares, diluting existing shareholders. Convertible notes offering.”

Increased leverage from convertible notes, though zero-coupon reduces immediate cash interest burden.

“Took on a material direct financial obligation, increasing leverage. 0.00% Convertible Senior Note due 2033.”

Net loss and negative free cash flow persist despite revenue growth.

“Net loss was $92.7 million for Q3 2025; free cash flow was $(45.8) million.” · word for word

Operating expenses increased significantly due to commercial expansion for Shield.

“Operating expenses were $270.6 million, up from $234.3 million in prior year.”

Continued operating losses

“We have incurred losses and negative cash flows from operations since our inception, and as of September 30, 2025, we had an accumulated deficit of $2.9 billion.” · word for word

Reimbursement dependency

“We submit claims to Medicare and private payers for reimbursement for our Guardant360 CDx... and Shield screening tests.” · word for word